Memantine in Moderate-to-Severe Alzheimer's Disease

20032,003 citationsJournal Articlebronze Open Access

Authors

‌Barry Reisberg · New York University

Rachelle S. Doody · Baylor College of Medicine

Albrecht Stöffler · MerLion Pharma (Germany)

Frederick A. Schmitt · University of Kentucky

Steven H. Ferris · New York University

Hans Jörg Möbius · MerLion Pharma (Germany)

Abstract

Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.

Topics & Keywords

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Neuroscience and Neuropharmacology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 348, Issue 14, pp. 1333-1341

DOI: 10.1056/nejmoa013128

Field-Weighted Citation Impact: 77.09